Adults

Individualized. Usually initiated at 0.2 units/kg once daily for type 1 diabetes or 0.2 units/kg once daily for type 2 diabetes, adjusted based on blood glucose levels. Doses are typically 10-18% lower when converting from Lantus U100 to Toujeo U300.

Elderly

No specific dose adjustment required, but close monitoring of blood glucose is recommended due to potential for greater insulin sensitivity and risk of hypoglycemia.

Renal_impairment

No specific dose adjustment for insulin glargine is required in patients with renal impairment, but blood glucose monitoring should be intensified, and the insulin dose adjusted individually.

Onset

Onset of action typically within 6 hours.

Excretion

Metabolites primarily excreted renally.

Half life

Terminal half-life is approximately 18-19 hours.

Absorption

Slow and prolonged absorption from subcutaneous injection site, resulting in a relatively constant concentration-time profile over 36 hours.

Metabolism

Partially metabolized in the subcutaneous tissue to two active metabolites (M1 and M2). Primarily metabolized in the liver.

Oral antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, angiotensin receptor blockers, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics

May increase insulin's glucose-lowering effect and risk of hypoglycemia.

Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, growth hormone, isoniazid, niacin, oral contraceptives, phenothiazine derivatives, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones

May decrease insulin's glucose-lowering effect.